Developing a new treatment for Angelman Syndrome using modified RNA technology
Engineering Chemically Modified RNPs for Effective Treatment of Angelman Syndrome
This study is testing a new way to treat Angelman Syndrome by using special tools to help turn on a gene that’s not working properly in the brain, with the hope of improving development for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Couragene, INC. NIH-funded |
| Lab location | 1 site (Edison, United States) |
| Project ID | NIH-10918729 on NIH RePORTER |
What this research studies
This research focuses on creating a novel treatment for Angelman Syndrome, a genetic disorder that leads to severe developmental delays. The approach involves using chemically modified ribonucleoproteins (cRNPs) to deliver CRISPR technology directly to brain cells, aiming to activate the UBE3A gene that is deficient in patients. By optimizing the formulation of these cRNPs, the researchers hope to achieve high efficiency in editing the genes of affected neuronal cells. This innovative method seeks to provide a safer alternative to current gene editing techniques that may have safety concerns.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Angelman Syndrome, particularly those with the genetic deficiency of the UBE3A gene.
Not a fit: Patients with other neurogenetic disorders or those without a confirmed diagnosis of Angelman Syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that addresses the underlying cause of Angelman Syndrome rather than just managing its symptoms.
How similar studies have performed: Previous research has shown promise in using CRISPR technology for gene editing in similar contexts, indicating potential success for this novel approach.
Where this research is happening
Edison, United States
- Couragene, INC. — Edison, United States (Active)
Researchers
- Principal investigator: Xie, Ying — Couragene, INC.
- Study coordinator: Xie, Ying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.